Zacks: Harvard Bioscience, Inc. (NASDAQ:HBIO) Receives Consensus Recommendation of “Buy” from Brokerages

Harvard Bioscience, Inc. (NASDAQ:HBIO) has been given an average broker rating score of 2.00 (Buy) from the two analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and one has given a strong buy rating to the company.

Analysts have set a 1 year consensus price target of $3.75 for the company and are predicting that the company will post $0.08 EPS for the current quarter, according to Zacks. Zacks has also assigned Harvard Bioscience an industry rank of 14 out of 255 based on the ratings given to related companies.

A number of brokerages recently weighed in on HBIO. ValuEngine downgraded shares of Harvard Bioscience from a “buy” rating to a “hold” rating in a research report on Tuesday, October 22nd. Zacks Investment Research lowered shares of Harvard Bioscience from a “buy” rating to a “hold” rating in a report on Wednesday, January 8th. Finally, Benchmark downgraded Harvard Bioscience to a “buy” rating in a research report on Monday, December 9th.

NASDAQ:HBIO traded up $0.03 during mid-day trading on Thursday, hitting $3.17. 472 shares of the stock traded hands, compared to its average volume of 61,653. The business’s 50-day moving average price is $2.98 and its 200 day moving average price is $2.71. The company has a market cap of $121.82 million, a PE ratio of 21.13 and a beta of 1.52. Harvard Bioscience has a 12-month low of $1.51 and a 12-month high of $4.66. The company has a quick ratio of 1.31, a current ratio of 2.41 and a debt-to-equity ratio of 0.78.

Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings results on Tuesday, November 5th. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). Harvard Bioscience had a negative net margin of 2.45% and a positive return on equity of 5.22%. The company had revenue of $27.42 million for the quarter, compared to analysts’ expectations of $28.50 million. Analysts anticipate that Harvard Bioscience will post 0.12 earnings per share for the current fiscal year.

In other Harvard Bioscience news, insider Value Fund Lp Palogic bought 66,868 shares of the stock in a transaction on Wednesday, November 13th. The shares were bought at an average price of $1.29 per share, with a total value of $86,259.72. Also, Director Bertrand Loy bought 12,855 shares of the company’s stock in a transaction dated Monday, November 11th. The stock was acquired at an average price of $2.59 per share, for a total transaction of $33,294.45. The disclosure for this purchase can be found here. Insiders bought 102,439 shares of company stock valued at $178,492 in the last three months. Company insiders own 5.40% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Engine Capital Management LP bought a new stake in Harvard Bioscience in the second quarter worth $3,736,000. Dalton Greiner Hartman Maher & Co. lifted its holdings in shares of Harvard Bioscience by 1,207.4% in the 2nd quarter. Dalton Greiner Hartman Maher & Co. now owns 1,155,376 shares of the medical instruments supplier’s stock worth $2,311,000 after buying an additional 1,067,007 shares during the period. Granahan Investment Management Inc. MA lifted its holdings in shares of Harvard Bioscience by 91.8% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 1,771,964 shares of the medical instruments supplier’s stock worth $5,449,000 after buying an additional 848,191 shares during the period. Millennium Management LLC grew its position in shares of Harvard Bioscience by 982.2% during the 3rd quarter. Millennium Management LLC now owns 645,331 shares of the medical instruments supplier’s stock worth $1,984,000 after buying an additional 585,701 shares in the last quarter. Finally, River & Mercantile Asset Management LLP bought a new position in shares of Harvard Bioscience during the 2nd quarter worth $1,114,000. 64.31% of the stock is currently owned by hedge funds and other institutional investors.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc provides scientific instruments, systems, software, and services used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, sample preparation plates and columns, and electroporation and electrofusion instruments under the Biochrom, BioDrop, Hoefer, Scie-plas, QuikPrep, and BTX brands.

Featured Article: What is Depreciation?

Get a free copy of the Zacks research report on Harvard Bioscience (HBIO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply